Drug Profile
Research programme: Alzheimer's disease therapeutics - EUSA Pharma
Alternative Names: TKP-1001Latest Information Update: 18 Jun 2012
Price :
$50
*
At a glance
- Originator EUSA Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 18 Jun 2012 Discontinued - Preclinical for Alzheimer's disease in United Kingdom (unspecified route)
- 09 Oct 2007 EUSA Pharma is seeking partnership/divestment opportunities for TKP 1001 in Alzheimer's disease (http://www.eusapharma.com)
- 09 Oct 2007 Preclinical trials in Alzheimer's disease in United Kingdom (unspecified route)